Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

BACKGROUND: CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall survival advantage. The similarly fully human anti-CTLA4...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2012
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3543342/
https://ncbi.nlm.nih.gov/pubmed/23171508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-236
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker